Rudolph M. Navari

Also affiliated with University of Mount Olive

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)”.

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

The Oncologist(2023)10.1093/oncolo/oyad140

N/A

0.229DataRank · unranked

3 citations

Jennifer Le‐Rademacher, Fabrice Smieliauskas, Kathryn J. Ruddy, Thomas J. Saphner, Heshan Liu +10 more

Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12107

N/A

0DataRank · unranked

1 citations

Jennifer Le‐Rademacher, Fabrice Smieliauskas, Kathryn J. Ruddy, Thomas J. Saphner, Heshan Liu +9 more